American International Group Inc. Has $4.54 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Posted by Defense World Staff on Jun 4th, 2023

American International Group Inc. cut its holdings in Omnicell, Inc. (NASDAQ:OMCL – Get Rating) by 0.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 90,080 shares of the company’s stock after selling 196 shares during the period. American International Group Inc. owned approximately 0.20% of Omnicell worth $4,542,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of OMCL. MetLife Investment Management LLC boosted its holdings in Omnicell by 55.4% in the first quarter. MetLife Investment Management LLC now owns 23,169 shares of the company’s stock worth $3,000,000 after purchasing an additional 8,257 shares in the last quarter. Rhumbline Advisers boosted its holdings in Omnicell by 6.4% in the first quarter. Rhumbline Advisers now owns 111,098 shares of the company’s stock worth $14,386,000 after purchasing an additional 6,657 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in Omnicell by 0.4% in the first quarter. Great West Life Assurance Co. Can now owns 37,956 shares of the company’s stock worth $5,036,000 after purchasing an additional 144 shares in the last quarter. Raymond James Trust N.A. boosted its holdings in Omnicell by 10.9% during the first quarter. Raymond James Trust N.A. now owns 3,881 shares of the company’s stock valued at $503,000 after acquiring an additional 382 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Omnicell by 0.6% during the first quarter. Dimensional Fund Advisors LP now owns 848,688 shares of the company’s stock valued at $109,901,000 after acquiring an additional 4,839 shares during the period.

Insider Buying and Selling

In related news, Director Joanne B. Bauer sold 13,115 shares of the stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $54.24, for a total value of $711,357.60. Following the completion of the transaction, the director now owns 28,096 shares of the company’s stock, valued at $1,523,927.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 2.76% of the company’s stock.

Omnicell Stock Up 1.5 %

Shares of OMCL opened at $73.98 on Friday. Omnicell, Inc. has a 52 week low of $46.11 and a 52 week high of $125.17. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.75 and a current ratio of 2.06. The firm has a market capitalization of $3.34 billion, a P/E ratio of -184.95, a P/E/G ratio of 10.38 and a beta of 0.89. The company has a 50-day simple moving average of $64.46 and a 200-day simple moving average of $57.06.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on OMCL shares. TheStreet upgraded shares of Omnicell from a “d+” rating to a “c-” rating in a report on Thursday, May 25th. Benchmark upgraded shares of Omnicell from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a report on Monday, February 27th. StockNews.com started coverage on shares of Omnicell in a report on Thursday, May 18th. They set a “hold” rating for the company. Finally, KeyCorp upped their price target on shares of Omnicell from $65.00 to $70.00 in a report on Wednesday, May 3rd. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $72.22.

Omnicell Profile

(Get Rating)

Omnicell, Inc engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and interoperability, central pharmacy dispensing, medication adherence, population health and point of care automation.

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.